NCT04551911: A trial that was reported late by OPKO Health, Inc.
This trial has reported, although it was 538 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04551911 |
|---|---|
| Title | A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 2, 2020 |
| Completion date | Oct. 8, 2021 |
| Required reporting date | Oct. 8, 2022, midnight |
| Actual reporting date | March 29, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 538 |